Clinical significance of fibronectin expression in colorectal cancer

Molecular Medicine Reports

Volumn 1, Issue 1, 2008, Pages 77-81

  Saito, Noboru ^a   Nishimura, Hajime ^b   Kameoka, Shingo ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Adhesion molecule; Colorectal cancer; Fibronectin; Hepatic metastasis; Serum fibronectin; Urinary fibronectin

Indexed keywords

FIBRONECTIN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; PREDICTIVE VALIDITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; SEROLOGY; SERUM; URINALYSIS; URINE;

EID: 69249154325     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Morrison PR, Edsall JT and Miller SG: The separation of purified fibrinogen from Fraction I of human plasma. J Am Chem Soc 70: 3103-3108, 1948.
2. Japanese Society for Cancer of the Colon and Rectum: Japanese Classification of Colorectal Carcinoma. 1st English edition, Kanehara & Co. Ltd, Tokyo, 1977.
3. Saito N and Kameoka S: Serum laminin is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 20: 238-244, 2005. (Pubitemid 40553002)
4. Nakazawa S, Saito N, Kameoka S and Kobayashi M: Clinical significance of matrix metalloproteinase (MMP)-2, -9 and E-cadherin expression for assessing the spreading of human colorectal cancer. J Tokyo Womens Med Univ 74: 26-32, 2004.
5. Hirosawa T, Saito N, Kameoka S and Kobayashi M: Clinical significance of epidermal growth factor (EGF) expression for assessing the spreading of human colon cancer. J Jpn Soc Coloproctol 55: 402-412, 2002.
6. Hashimoto T, Saito N, Kameoka S, Shibata N and Kobayashi M: Clinical significance of hepatocyte growth factor and its specific receptor c-Met expression in colorectal cancer progression. Acta Histochem Cytochem 37: 139-146, 2004. (Pubitemid 38470676)
7. Daiko W, Saito N and Kameoka S: Clinical significance of TGF-β1 expression in evaluation of the malignancy of colorectal cancer. J Jpn Soc Coloproctol 58: 377-382, 2005.
8. Yamada A, Saito N, Kameoka S and Kobayashi M: Clinical significance of epidermal growth factor (EGF) expression in gastric cancer. Hepatogastroenterology 54: 1049-1052, 2007. (Pubitemid 47013902)
9. Haglund C, Ylatupa S, Mertaniemi P and Partanen P: Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA. Br J Cancer 76: 777-783, 1997. (Pubitemid 27379746)
10. Hegele A, Heidenreich A, Varga Z, et al: Cellular fibronectin in patients with transitional cell carcinoma of the bladder. Urol Res 30: 363-366, 2003. (Pubitemid 36285652)
11. Menendez V, Fernandez-Suarez A, Galan JA, Perez M and Garcia-Lopez F: Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology 65: 284-289, 2005. (Pubitemid 40248014)
12. Webb KS and Lin GH: Urinary fibronectin: potential as a biomarker in prostatic cancer. Invest Urol 17: 401-404, 1980.
13. Malmstrom PU, Larsson A and Johansson S: Urinary fibronectin in diagnosis and follow-up of patients with urinary bladder cancer. Br J Urol 72: 307-310, 1993. (Pubitemid 23280597)
14. Sanchez-Carbayo M, Urrutia M, Gonzalez de Buitrago JM and Navajo JA: Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer. Clin Cancer Res 6: 3585-3594, 2000. (Pubitemid 30694941)
15. Kirkali G, Tuzel E, Guler C, Gezer S and Kirkali Z: Significance of tissue laminin P(1) elastase and fibronectin levels in transitional cell carcinoma of the bladder. Eur Urol 39: 292-299, 2001. (Pubitemid 32245369)
16. Wunderlich H, Reichelt O, Zermann DH, Schubert J, Berndt A and Kosmehl H: Fetal fibronectin: a new screening-marker for bladder cancer? Oncol Rep 8: 669-672, 2001.
17. Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O and Khalifa A: Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol 168: 465-469, 2002. (Pubitemid 34793273)
18. Katayama M, Kamihagi K, Nakagawa K, et al: Increased fragmentation of urinary fibronectin in cancer patients detected by immunoenzymometric assay using domain-specific monoclonal antibodies. Clin Chim Acta 217: 115-128, 1993. (Pubitemid 23274402)
19. Saito N, Mitsuhashi M, Hayashi T, et al: Inhibition of hepatic metastasis in mice treated with cell-binding domain of human fibronectin and angiogenesis inhibitor TNP-470. Int J Clin Oncol 6: 215-220, 2001. (Pubitemid 33111357)